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Abstract
Background: Lerisetron, a competitive serotonin type 3 receptor (5-HT3R) antagonist, contains
five functional groups capable of interacting with amino acids in the 5-HT3R binding site. Site
directed mutagenesis studies of the 5-HT3AR have revealed several amino acids that are thought
to form part of the binding domain of this receptor. The specific functional groups on the ligand
that interact with these amino acids are, however, unknown. Using synthetic analogs of lerisetron
as molecular probes in combination with site directed mutagenesis, we have identified some of
these interactions and have proposed a model of the lerisetron binding site.
Results: Two analogs of lerisetron were synthesized to probe 5-HT3R functional group
interactions with this compound. Analog 1 lacks the N1 benzyl group of lerisetron and analog 2
contains oxygen in place of the distal piperazine nitrogen. Both analogs show significantly decreased
binding affinity to wildtype 5-HT3ASRs. Mutations at W89, R91, Y142 and Y152 produced significant
decreases in binding compared to wildtype receptors. Binding affinities of analogs 1 and 2 were
altered only by mutations at W89, and Y152.
Conclusions: Based on the data obtained for lerisetron and analogs 1 and 2, we have proposed a
tentative model of the lerisetron binding pocket of the 5-HT3ASR. According to this model, The Nbenzyl group interacts in a weak interaction with R91 while the benzimidazole group interacts with
W89. Our data support an interaction of the distal amino nitrogen with Y142 and Y152.

Background
The cysteine-loop family of ligand gated ion channels
(LGIC) is comprised of receptors with pentameric quaternary structure and at least two ligand binding sites present
at the subunit interfaces [1,2]. This receptor family is characterized by the presence of a critical disulfide loop struc-

ture within the binding site and an integral ion selective
channel. LGIC receptors are found in both the peripheral
and central nervous systems. Members of this family include the acetylcholine receptors [3,4], the γ-amino butyric acid type A receptor (GABAAR) [5], and the glycine
receptor (GlyR) [6].
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The first subunit of the 5-HT3R was cloned in 1991 [7].
The sequence of this subunit was shown to be highly homologous to LGIC receptors and thus identified the 5HT3R receptor as another member of this superfamily [7–
9]. Similar to other LGIC receptors, more than one subtype has been identified. Two splice variants of an A subunit (long and short forms), and a single B subunit have
been cloned [10–13]. Both the long and short forms of the
A subunit are capable of forming functional homomeric
receptors [5-HT3ALR and 5-HT3ASR] although some differences between an agonist and partial agonist activity have
been observed [14]. A third subtype is formed by a combination of the A and B subunits to produce a heteromeric
receptor of unknown stoichiometry [10]. Heteromeric receptors are pharmacologically and functionally distinct
from the homomeric 5-HT3AL and 5-HT3AS receptors [11].
5-HT3Rs are distributed throughout the central and peripheral nervous system, playing a significant role in phenomenon such as anxiety, emesis and alcoholism.
Antagonists to 5-HT3Rs are clinically efficacious in the
treatment of chemotherapy-induced emesis [15] and recent studies on human subjects have suggested their potential application in the treatment of early onset
alcoholism [16,17].
Hibert et al proposed an early model for the antagonist
pharmacophore of the 5-HT3R [18]. According to this
model, all 5-HT3R antagonists contain an aromatic ring, a
carbonyl oxygen or bioisosteric equivalent, and a basic nitrogen. According to Hibert's model, the basic nitrogen is
located 5.2A° from the centre of the aromatic ring and approximately 1.7A° above plane of the ring. The carbonyl
oxygen and the aromatic ring are coplanar and separated
by a distance of 3.3A°. Recent studies have expanded on
this model to include another lipophilic region and a second hydrogen bonding interaction two atoms away from
the first [19–21]. A compound that contains all five pharmacophoric regions was synthesized by Orjales et al[22].
This compound (1-(phenylmethyl)-2-piperizinyl benzimidazole or lerisetron) is shown in figure 1 and is a potent 5-HT3R antagonist. Functional groups on this
compound capable of forming interactions with the receptor are the distal amino group, a benzimidazole and a
benzyl group in the N1 position of the benzimidazole.
While Lerisetron contains no carbonyl group, the second
nitrogen contained in the benzimidazole heterocycle
could act as bioisostere of this functional group [22]. Orjales demonstrated the importance of the N-benzyl group
by synthesizing several N1 substituted analogs of Lerisetron. Removal of the N-benzyl group produced a 80-fold
decrease in affinity, indicating a role for this group in interacting with the 5-HT3R. Other studies have supported
this observation and suggest a more specific electrostatic
interaction [23].
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While structure-activity relationship studies and molecular modeling have led to the development of a detailed
pharmacophore model, determining specific point interactions between 5-HT3 antagonists and binding site amino acids has proven difficult. Mutagenesis studies have
identified the interaction of amino acids W89 and R91 in
the binding of 5-HT3R ligands [24,23]. Studies conducted
in our laboratory have identified three additional putative
binding site residues (Y140, Y142, and Y152) [25]. W89
and R91 are present in a conserved region of LGIC receptors often referred to as loop D [24,26]. Similarly, Y140,
Y142 and Y152 are located in the region homologus to E
loop region of nicotinic AchR.
In this study, we have endeavoured to identify the amino
acids interacting with the different functional groups
present on the lerisetron molecule in order to develop a
model for interaction of this compound with the 5-HT3R.
Using site directed mutagenesis in combination with analogs of lerisetron, we have identified amino acids that appear to interact selectively with the terminal amino group,
the N-benzyl group and the aromatic benzimidazole.

Results
Functional activity of lerisetron
Whole cell patch-clamp experiments were performed to
test the functional activity of lerisetron. No response was
observed when lerisetron was applied alone (data not
shown). When co-applied with 5-HT, lerisetron inhibited
the absolute magnitude of the response with no apparent
alteration of the response profile (Figure 2). The combination of several identical inhibition experiments produced
a Ki value of 0.2 ± 0.03 nM for lerisetron inhibition of the
5-HT induced response. These data correspond well with
previously reported data for this compound [22] and verify the competitive antagonist action of lerisetron. Analogs of lerisetron have been shown to inhibit 5-HT3Rs in
a similar manner [23].
Importance of the N-benzyl and distal piperazine nitrogen
to binding of lerisetron
The Ki value for lerisetron inhibition of [3H]-granisetron
binding to wildtype receptors was determined to be 0.8 ±
0.19 nM (Figure 3 and Table 1). This value agrees with
previously published data for this compound. The Ki values for analogs 1 and 2 under identical conditions are 25
± 3.2 nM and 320 ± 82 nM respectively (Figure 4A, Table
1). The observed change in Ki represents the decreases in
binding energy resulting from removal of the N-benzyl
group (analog 1) and the distal piperazine nitrogen (analog 2).
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Figure 1
5-HT3R antagonists. Granisetron and Lerisetron are shown along with the two analogs utilized to probe the functional
group interactions of binding site amino acids. Analog 1 lacks the N-benzyl functional group. Analog 2 contains oxygen in place
of the distal piperazine nitrogen.

Identification of amino acids interacting with Lerisetron
In order to determine the nature of the amino acids interacting with the distal amino and N-benzyl groups of lerisetron, we constructed 5-HT3ASRs containing mutations at
W89, R91, Y140, Y142 and Y152. Figure 3 shows inhibition of [3H]-granisetron binding by lerisetron on wildtype
and mutant receptors. For most amino acids, an alanine
substitution was constructed in order to effectively remove any amino acid interaction with the ligand. For
W89, an alanine substitution has been shown to prevent
binding of [3H]granisetron; therefore a less severe mutation was constructed.

The W89F mutation produces a 18-fold change in Kd for
[3H]-granisetron binding (18 ± 2 nM) and the W89Y mutation produces a 5.8-fold change in Kd (5.7 ± 0.7 nM).
Mutation of amino acid R91 to alanine produced a 5-fold
change in Kd for [3H]granisetron binding (4.9 ± 0.7 nM)
(Table 1). These data agree well with previously reported
values [24]. Alanine mutations at the tyrosine positions
Y140, Y142 and Y152 also produced minor increases in
Kd for [3H]granisetron binding (2.7 ± 0.19 nM, 4.5 ± 0.5
nM and 7.8 ± 1.1 nM respectively) [25] (Table 1).
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1 nA
0.1 s
4 mM 5-HT + 0.3 nM lerisetron

4 mM 5-HT

Figure 2
Inhibition of 5-HT induced responses by Lerisetron. tsA 201 cells transfected with 5-HT3ASR cDNA were clamped at a
holding potential of -60 mV and perfused with 4 µM 5-HT (lower trace) or 4 µM 5-HT and 0.3 nM lerisetron (upper trace).
Lerisetron reduced the peak 5-HT induced currents from 2.0 nA to 1.0 nA with no change in the response characteristics. An
IC50 value was determined by a combination of similar experiments and determined to be 0.4 ± 0.03 nM.

Only small changes in Ki for lerisetron were observed for
the Y140A mutation while the Y142A and Y152A mutations produced large increases in the Ki (Table 1 and Figure 3). For W89F and W89Y, the changes in Ki observed
for lerisetron were much smaller than for the alanine mutations at Y142A and Y152A, as would be expected for the
less severe nature of these mutations. The changes were,
however significant (p < 0.001 in both cases) and are similar to the changes in Kd reported for [3H]granisetron. The
increase in Ki on the W89F mutant receptor was 4.8 ± 0.56
fold and the increase in Ki on the W89Y receptor was 3.6
± 0.4 fold. The R91A mutant produced an increase in Ki of
7.6 ± 1.5 fold as compared to the wildtype receptor. These
data indicated potential interactions of lerisetron with
W89, R91, Y142 and Y152.
Mutation of W89
As mentioned above, the lack of [3H]-granisetron binding
to W89A mutant receptors necessitated the use of W89F
and W89Y mutations to analyze functional group interactions. The effects of these mutations on the Ki for analogs
1 and 2 are shown in figure 4B, 4C and Table 1. Analog 1
inhibited [3H]-granisetron binding to W89F receptors
with a Ki of 170 ± 54 nM (7 ± 3.2 fold increase, p < 0.001)
and W89Y receptors with a Ki of 81 ± 14 nM (3.2 ± 0.6
fold increase, p < 0.001). This reflects a significant increase in Ki and reflects a potential interaction of analog 1
with W89. The strength of this interaction is apparently
similar to the strength of the interaction with [3H]-granisetron and lerisetron since the magnitude of the change is

similar in both cases. Analog 2 also showed a significant
increase in Ki as a result of the W89F and W89Y mutations. The magnitude of the change for W89F (5.1 ± 1.3
fold, p < 0.05) was similar to that observed for lerisetron
and analog 1. The W89Y mutation produced a 6.8 ± 1.6
fold change in Ki (p < 0.05). Thus, all three compounds
appear to form similar interactions with W89.
Mutation of R91
Mutation of R91 to alanine (R91A) resulted in a significant, but small increase in Ki for lerisetron of 7.6 ± 1.5 fold
(p < 0.01). Figure 4D shows the inhibition of [3H]-granisetron binding by analogs 1 and 2 at R91A mutant receptors. No significant change in Ki was observed on these
receptors for either analog 1 (0.9 ± 0.28 fold) or analog 2
(0.56 ± 0.14 fold) (Table 1) as compared to the wildtype
receptor.
Mutation of Y142
Mutation of Y142 to alanine produced one of the largest
observed changes in Ki for lerisetron (Figure 3 and Table
1). The Ki obtained for lerisetron was 130 ± 28 nM, reflecting a change of 160 ± 37 fold compared to wildtype receptors. The Ki value for analog 1, in contrast, increased only
6.8 ± 2.3 fold (p < 0.01) as a result of this mutation (Figure 4E and Table 1). The Ki for analog 2 showed a similar
change of 17 ± 0.77 fold (p < 0.01). While these Ki values
are significantly different from wildtype values for each
analog, the lack of larger effects suggests that neither analog 1 nor analog 2 bind as strongly as lerisetron to Y142.
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Figure 3
Inhibition of [3H]-granisetron binding to mutant and wildtype receptors by lerisetron. Competition binding assays
were performed as described in Materials and Methods. Each point represents a mean ± SE of n>4 experiments. Ki values calculated from this data and the relative magnitude of the shift in Ki compared to wildtype receptors are shown in Table 2.
Y140A produced no significant change in Ki values. W89F, W89Y and R91A mutations produced moderate increases in Ki.
Y142A and Y152A mutations resulted in increases in Ki of 160 and 190 fold respectively.
Mutation of Y152
The Y152A mutation showed the most variability in its effects on Ki values for lerisetron, analog 1 and analog 2
(Figure 3, Figure 4F and Table 1). Lerisetron inhibited
[3H]-granisetron binding with a Ki value of 150 ± 36; an
increase of 190 ± 43 fold compared to wildtype values.
The Ki value for analog 1 increased from 25 ± 3.2 nM
(wildtype) to 2.5 ± 0.40 µM. This change of 100 ± 16 fold
is slightly smaller, but not significantly different from the
relative change observed for lerisetron. The Ki for analog 2
increased from 0.32 ± 0.08 µM on wildtype to 13 ± 4.2 µM
on Y152A mutant receptors (40 ± 12 fold increase). The
increase observed for analog 2 was significantly less than
that observed for both lerisetron and analog 1. The smaller change in Ki for analog 2 suggests that analog 2 binds
weakly to Y152 while lerisetron and analog 1 bind more
tightly.

Discussion
The purpose of this study was to ascertain the functional
group interactions of lerisetron with specific amino acids
present in the 5-HT3R binding site. To this end, we examined the effects of specific amino acid mutations on the
binding of lerisetron and two analogs. These analogs,
shown in Figure 1, are identical to lerisetron in structure;
however, each analog lacks a single functional group
found in lerisetron. By comparing the effects of a specific
amino acid mutation on the Ki for inhibition of [3H]granisetron binding, we can begin to identify the functional groups likely to participate in that interaction. Five
different amino acids were tested: W89, R91, Y140, Y142
and Y152. Each of these amino acids has been shown in
previous studies to alter the binding of 5-HT3R ligands
[24,25]. A summary of the changes in Ki is presented as a
bar chart in Figure 5A and 5B.
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Figure 4
Inhibition of [3H]-granisetron binding to wildtype and mutant receptors by analog 1 and analog 2. Competition
binding assays were performed as described in Materials and Methods. Each point represents a mean ± SE of n> 4 experiments.
IC50 values were determined from the data and a Ki value calculated using the Cheng-Prusoff equation. Ki values for inhibition
on each mutant are shown in Table 1 for all three compounds. A. Wildtype B. W89F C. W89Y D. R91A E. Y142A F. Y152A
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Table 1: Summary of inhibition data obtained for lerisetron, analog 1 and analog 2 on mutant and wildtype receptors. Ki values were
calculated from IC50 values as previously described. All data is the result of n > 4 experiments and is expressed as the mean ± SE. The
relative change in Ki was calculated as the Ki (mutant) / Ki (wildtype) and indicates the increase in Ki relative to wildtype ± SE. * indicates
significant difference in fold change value. Kd values for [3H]granisetron binding to wt and mutant receptors were reproduced from
reference 25.

Ligand

Amino acid
WT
W89F
W89Y
R91A
Y140A
Y142A
Y152A

[3H] Granisetron

Kd (nM)
0.98 ± 0.12
5.7 ± 0.7
18 ± 2.0
4.9 ± 0.7
2.7 ± 0.2
4.5 ± 0.5
7.8 ± 1.1

Fold change
1
5.8 ± 0.7
18 ± 2.1
5 ± 0.8
2.8 ± 0.3
4.6 ± 0.5
8 ± 1.1

Lerisetron

Ki (nM)
0.8 ± 0.19
3.8 ± 0.46
2.8 ± 0.14
6.1 ± 1.16
2.1 ± 0.33
130 ± 28
150 ± 36

Analog 1

Fold change
1
4.8 ± 0.56*
3.5 ± 0.38*
7.6 ± 1.45*
2.6 ± 0.37
160 ± 37
190 ± 43

While lerisetron binds to wildtype receptors with high affinity, analog 1 binds with lower affinity (31 fold increase
in Ki compared to lerisetron). Analog 2, which lacks the
terminal nitrogen of lerisetron, binds with even lower affinity (a 400-fold fold increase in Ki compared to lerisetron – Table 1). These data demonstrate the relative
importance of the N-benzyl and the terminal nitrogen
moieties for lerisetron binding. Cation-pi interactions involving aromatic residues and a quaternary ammonium
have been demonstrated to play a major role in binding
of nicotinic ligands to nAchRs [29,30]. Our data support
a similar role for Y142 and Y152 in binding of lerisetron
to the 5-HT3A receptor.
Functional group interactions of W89
The W89F mutation produced a significant increase in Ki
for all three compounds. The magnitude of the change
was similar in all cases. In addition, the increase in Ki was
identical to the increase in Kd that has been observed for
[3H]granisetron binding on this mutant [24]. Alterations
in Ki resulting from the W89Y mutation were slightly less,
however the change was again the same for lerisetron, analog 1 and analog 2. These data suggest that all three compounds form binding site interactions with W89. The
interaction between lerisetron and W89 is unlikely to be
via the N-benzyl functional group since the Ki for analog
1 was also altered by this mutation. The same argument
can be made for the distal piperazine nitrogen since the Ki
for analog 2 also increased. The portion of the molecule
common to all three compounds, the aromatic benzimidazole, is thus the most likely point of interaction for
W89.
Functional group interactions of R91
The R91A mutation increased the Ki value for lerisetron
inhibition of [3H]granisetron binding by 7.6 fold. This is

Ki (nM)
25 ± 3.2
170 ± 54
81 ± 14
22.7 ± 8
88 ± 45
170 ± 58
2500 ± 400

Analog 2

Fold change
1
7.0 ± 3.2*
3.2 ± 0.6*
0.9 ± 0.28
3.5 ± 1.7
6.8 ± 2.3*
98 ± 16

Ki (nM)
320 ± 82
1600 ± 400
2200 ± 520
180 ± 27
470 ± 210
5500 ± 240
13000 ± 4200

Fold change
1
5.1 ± 1.3*
6.8 ± 1.6*
0.56 ± 0.14
1.4 ± 0.65
17 ± 0.77
40 ± 12

a moderately small change for an alanine mutation, particularly considering that the smallest change in Ki for removal of a functional group on lerisetron (the N-benzyl
group) was 31 fold. It is therefore likely that this interaction is either extremely weak or the change in Ki is the result of a structural change in the binding site. Previous
studies concluded that R91 was an important interaction
for the 5-HT3R agonist 5-hydroxytryptamine (5-HT),
since the Ki for 5-HT inhibition increased over 3000 fold
as a result of the R91A mutation [24]. A change in Kd for
[3H]granisetron binding to R91A was also observed. In order to determine whether the N-benzyl or distal piperazine nitrogen of lerisetron was involved in an interaction
with R91, we tested both analog 1 and 2 on R91A mutant
receptors. No change in Ki was observed for either compound. This result makes it much more difficult to assign
the correct functional group to this amino acid since it
suggests that one or both of the compounds is no longer
binding the receptor in precisely the same manner as lerisetron. Considering the small change observed for lerisetron binding as a result of this mutation, even a slight
reorientation of the molecule in the binding site could result in the loss of this interaction.
Functional group interactions of Y142
The Ki values for inhibition of [3H]granisetron binding by
analogs 1 and 2 were altered only slightly by the Y142A
mutation. The magnitude of the increase in Ki for lerisetron, however, was considerably larger (160 fold) and is
indicative of an important interaction of the compound
with Y142. The lack of a large change in Ki for both analogs makes it difficult to interpret this data since one or
both of the compounds appears to be interacting differently with the binding site than lerisetron.
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Figure 5
Relative increases in Ki for lerisetron, analog 1 and analog 2 on mutant and wildtype receptors. The relative
change in Ki was determined as Ki (mutant)/ Ki (wildtype) for each compound. A. W89Y, W89F, R91A B. Y140A, Y142A,
Y152A. Lerisetron showed a significant increase in Ki for all mutants except Y140A. Increases in Ki were observed for analog 1
and 2 on W89 and Y152A.
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Analogs 1 and 2 differ from each other both in the functional groups contained in the molecule and their structural similarity to lerisetron. Analog 2 is most similar in
overall structure. The substitution of oxygen for the distal
amino nitrogen alters the potential interactions formed at
this position, but is likely to have a small effect on the
overall size and shape of the molecule. Analog 1 is far less
similar to lerisetron and more similar to the 5-HT3R antagonist granisetron. Previous studies have shown that the
binding of granisetron is not affected by the Y142A mutation [25]. Analog 1 may bind more similar to granisetron
than lerisetron and thus would be unaffected by mutations at Y142. This is less likely to be the case with analog
2.
The strength of the putative interaction at Y142 can be
identified by examining the change in binding of lerisetron as a result of the Y142A mutation. The Y142A mutation produced a 160 fold change in Ki. This change reflects
the binding energy lost as a result of the alanine substitution. The observed change in Ki on wt receptors is much
larger than that observed for removal of the N-benzyl
group (31 fold), but is similar to that observed for substitution of the distal amino nitrogen in analog 2 (400 fold).
Taken together with the close structural similarity of analog 2 to lerisetron, it can be concluded that comparison of
analog 2 and lerisetron should provide the best means of
identifying the interaction at Y142. No change in Ki was
observed for analog 2 as a result of the Y142A mutation
indicating a lack of any significant interaction of this compound with Y142. These data support our hypothesis that
Y142 interacts with the distal piperazine nitrogen of lerisetron. A second amino acid may also be involved since
the change in Ki for lerisetron binding as a result of the
Y142A mutation was smaller than the change produced
by substitution of the piperazine nitrogen. As described
below, one candidate for this second amino acid is Y152.
Functional group interactions of Y152
The Y152A mutation produced increases in Ki for all three
compounds although the magnitude of the change differed. The increases in the Ki values were 190 fold for lerisetron, 98 fold for analog 1 and only 40 fold for analog
2. Thus, analog 1 retains much of its ability to interact
with Y152 despite the absence of the N-benzyl group,
while analog 2 interacts more weakly with this amino acid. Since the Ki for analog 1 is increased by the Y152A mutation, it is unlikely that the N-benzyl group interacts with
Y152. The small change in Ki for analog 2 supports a partial interaction of Y152 with the distal piperazine nitrogen
although some interaction with another group is also apparent. This other group would be expected to be in close
proximity to the distal nitrogen. The most likely candidate
is the other nitrogen of the piperazine ring. Thus Y152A

http://www.biomedcentral.com/1471-2091/3/16

may form a partial interaction with both piperazine nitrogens.

Conclusions
Figure 6 shows a hypothetical model of the lerisetronbinding site supported by our observations. The model illustrates the secondary structure of the region of the receptor from Y140 – Y152 in a loop configuration. This
structure is supported by site-directed mutagenesis data
[25] as well as structural predictions obtained from other
LGIC receptors [31]. The recent determination of the
structure of a nicotinic acetylcholine binding protein [27]
that shares significant homology with the LGIC family
also supports a loop structure in this part of the protein.
The region from W89 through Y93 is shown as a β-sheet
as has been hypothesized based on site-directed mutagenesis studies of this strand of the 5-HT3R [24]. Our data indicate the functional groups of lerisetron that may interact
with W89, R91, Y142 and Y152.

Y140

Y142

H
N
N

N

Y152

N
R146

W89
E148
R91

G147

Y93

Figure 6
Model of the 5-HT3R binding site. The model illustrates
the major points discussed in the text. Lerisetron is shown
spanning the region between the D and E loops of the receptor. Both loops are illustrated as β-sheets as described. The
side chains are presumed to point in or out of the page
depending on their position. W89, R91, Y140, Y142 and
Y152 all presumably extend into the binding site. The terminal piperazine nitrogen is shown interacting primarily with
Y142, but is also capable of forming an interaction with Y152.
Y152 may also form an interaction with the second piperazine nitrogen. W89 is illustrated as forming an aromatic
interaction with the benzimidazole. While R91 is shown in
close contact to the N-benzyl group, the data support only a
weak interaction at this point.
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W89 is shown interacting with the aromatic benzimidazole group of lerisetron although the precise position of
W89 relative to this group is not known. The W89 interaction with this group is supported by the observed increase
in Ki for lerisetron, analog 1 and analog 2. Since the benzimidazole group is common to all three compounds it is
the most likely point of interaction. W89 also represents a
common interaction in the binding site for both lerisetron
and [3H]granisetron.
Y142 is shown interacting with the distal piperazine nitrogen possibly through a cation-π interaction. This orientation of an amino group interacting with an aromatic
amino acid in a cation-π interaction has been shown for
the nicotinic acetylcholine receptor and has been hypothesized for many LGIC receptors [28–30,26]. This conclusion is based on both the magnitude of the change
observed on the wild type receptor for removal of the amino group (400 fold) compared to the effect of the Y142A
mutation on lerisetron binding (160 fold) and the lack of
any major change in Ki for analog 2 as a result of this mutation. Our data does not support an interaction of this
amino acid with either the N-benzyl or benzimidazole
portions of lerisetron.
Y152 is shown positioned between the two piperazine nitrogens. This conclusion is supported by the smaller increase in Ki for analog 2 (40 fold) compared to that
observed for lerisetron (190 fold). These results suggest a
partial interaction of Y152 with the distal piperazine nitrogen. Since some change was observed, a second interaction is also likely. The functional group in closest
proximity to the distal piperazine nitrogen is the other nitrogen on the piperazine ring. Another possibility would
be the N-benzyl interaction, however, since the Y152A
mutation also produced a large increase in Ki for analog 2,
this conclusion is not supported by our data.
R91 is shown as interacting with the N-benzyl group. This
is a difficult conclusion to make considering the small effect of the R91A mutation on lerisetron binding. The interaction is included in the model based on structural
information obtained from the crystal structure of AChBP
[27]. The region of this protein homologous to loop E and
loop D of the 5-HT3A receptor suggests a loop structure
from Y140 to Y152 and a 3-residue turn containing a glycine at position 147 and the β-strand from W89 through
Y93 oriented as shown in Figure 6. The orientation of lerisetron between W89 and Y142A as shown would enable
the N-benzyl group to be positioned in close proximity to
R91. If this is the case, then a small alteration in position
of analog 1 or 2 in the binding site could result in the loss
of this presumably weak interaction. The apparent alterations in the binding site location of analog 1 would be
consistent with this hypothesis. An alternate hypothesis
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would place the N-benzyl group in a different position,
interacting with another amino acid; either solely or in
concert with R91.
Our data support a binding site for lerisetron on the 5HT3R that spans the D and E loop regions. Table 2 shows
the sequence alignment for the 5-HT3R, the α7 receptor
and the AChBP for these loops. Sequence alignment of
mouse 5-HT3 AR, α7 nAchR and AChBP result in alignment of the proposed D and E loop of the 5-HT3 AR with
corresponding regions of the α7 nAchR and AChBP. The
amino acids W89, R91 Y140, Y142 and Y152 of the 5HT3
A R can be aligned with W53, Q55, L102, R104, and M114
of the AChBP (Figure 6). These amino acids form a cluster
in the proposed acetylcholine binding domain of AChBP
similar to that proposed in our model. Both loops have
been identified on the complementary face of the binding
site of the nAChR. It is unknown if lerisetron utilizes amino acids on the principal face although none have been
identified. The model for lerisetron binding will be further refined as its interactions with other binding site amino acids are investigated [26,32,33]. Of particular interest
would be potential interactions of the N-benzyl group
that would account for the decrease in binding affinity of
analog 2. Additional information gained from comparison of our model with the recent crystal structure of the
AChBP demonstrates that lerisetron can be roughly 'fit'
into the binding site such that all the residues line up as
shown in our model. While this is not direct evidence that
the model is correct, subsequent molecular modeling of
the data presented in this paper may provide further support for our hypothesis. Our current model provides an
initial working hypothesis that can form the basis of further investigation. Also, while it is unclear whether the information obtained in this study can be extended to other
5-HT3R ligands, a similar approach would be useful in
identifying functional group interactions for mCPBG, 5HT, dtC and granisetron.

Materials and Methods
Mutagenesis
Wild type 5-HT3AS mouse receptor cDNA was derived
from N1E-115 neuroblastoma cells as previously described [24]. Mutant receptors were constructed using
polymerase chain reaction (Quick change mutagenesis
kit, Promega). All mutations were confirmed by DNA sequencing.
Cell culture methods and transfections
tsA201 cells (a derivative of the HEK293 cell line) were
grown in Dulbecco's modified Eagles medium (D-MEM)
containing 10% FBS and 100-units/ml penicillin/streptomycin. Cultures were maintained in humidified atmosphere of 5% CO2 at 37°C. For binding studies, tsA201
cells were plated at a density of 5 × 106 cells/75 cm2 and
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Table 2: Sequence alignment of the mouse 5-HT3R with the mouse nicotinic α7 receptor and the AChBP. Two sequences are shown.
The top sequence is the putative D loop containing W89 and R91 (homologous to W53 and Q55 of the AChBP). The lower sequence
shows the putative E loop and contains Y140, Y142 and Y152 (homologous to L102, R104 and M114 of the AChBP).
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grown for 9 hours prior to transfection. Cells were transfected with 10 µg murine 5-HT3ASR cDNA using calcium
phosphate co-precipitation (New Life Technologies, NY),
then incubated 36 hours prior to harvesting. For whole
cell patch clamp experiments, tsA201 cells were plated at
a density of 0.25 × 106 cells/27 cm2 dish and grown 12
hours prior to transfection. Cells were washed with fresh
culture medium then transfected with 10 µg 5-HT3ASR
cDNA using Qiagen Superfect transfection reagent (Qiagen, CA). Transfected cells were incubated with this mixture for 2.5 hours, then divided into 35 mm culture dishes
at a density of approximately 5 × 104 cells/dish and incubated for 24 hours at 37°C before recording.
Radioligand Binding Assay
Transfected cells were scraped from the dishes, washed
twice with Dulbecco's PBS (New Life Technologies, NY),
then resuspended in 1.0 ml PBS/100 mm dish. Cells were
either used fresh or frozen at this step until needed. Immediately prior to use, cells were homogenized in PBS using
a glass tissue homogenizer then centrifuged at 35 000 × g
for 30 minutes in a Beckman JA20 rotor. Membranes were
washed once more with PBS then resuspended in 1 ml
PBS/100 mm dish. Protein content was determined using
a Lowry assay (Sigma. Diagnostics, St. Louis, MO). Binding assays were performed in PBS. For Kd determinations,
100 µl of homogenate was incubated at 37°C for 1 hour
with varying concentrations of [3H] granisetron (NEN,
MA). Specific binding of [3H] granisetron was determined
as the bound [3H] granisetron not displaced by a saturating concentration of a competing ligand (100 µM mCPBG

or 10 µM MDL-72222). Kd values were determined by fitting the binding data to the following equation using
GraphPad PRISM (San Diego CA): B = Bmax [L] n / ([L] n
+ Kn), where θ is bound ligand, Bmax is the maximum
binding at equilibrium L is the free ligand concentration
and n is the Hill coefficient. For Ki determinations, 100 µl
of homogenate was incubated at 37°C for 2 hours with
varying concentrations of inhibitor and [3H] granisetron
(NEN, MA). Binding was terminated by rapid filtration
onto a GF/B filters. The IC50 values were calculated by fitting the data to the following equation using GraphPad
PRISM (San Diego CA): θ = 1/ (1+(L/IC50)), where θ is the
fractional amount of [3H] granisetron bound in the presence of inhibitor at concentration L as compared to the
amount of [3H] granisetron bound in the absence of inhibitor. IC50 is the concentration at which θ = 0.5. The Ki
is calculated from the IC50 value using the Cheng-Prusoff
equation.
Electrophysiological Methods
Transfected tsA201 cells were transferred to a recording
chamber and submerged in extracellular recording buffer
containing 25 mM HEPES pH 7.4, 140 mM NaCl, 1.7 mM
MgCl2, 5 mM KCl, 1.8 mM CaCl2. Patch electrodes (2–2.5
MΩ) were filled with intracellular recording buffer containing 25 mM HEPES pH 7.4, 145 mM KCL, 2 mM MgCl2
and 1 mM EGTA. Cells were clamped in whole cell configuration at a holding potential of -60 mV. Currents elicited
by agonist application were measured using an Axopatch
200B amplifier (Foster City, CA) under computer control
(DataPac 2000, RUN Technologies). Agonists and antago-
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nists were dissolved in extracellular solution and delivered to cells using a rapid perfusion system (Warner
Instruments, Hamden, CT). For EC50 determinations, responses were normalized to the maximum response obtained from the full agonist 5-HT and fitted to the
equation Ψ= 1/1+(EC50/ [C] n), where Ψ is the normalized current at 5-HT concentration [C], EC50 is the concentration of 5-HT needed to obtain half maximal
activation and n is the apparent Hill coefficient. For inhibition experiments, cells were exposed to inhibitor alone
for 30 s prior to co-exposure with 5-HT. Inhibited responses were calculated as a fraction of the response to 5HT alone. Data were plotted as the fractional response versus the concentration of inhibitor and analysed using
GraphPad software. The IC50 value was calculated as the
concentration of antagonist inhibiting the 5-HT evoked
response by 50%. A Ki value was calculated from the IC50
using the Cheng-Prusoff equation.
Synthesis of Lerisetron and its analogs
All target molecules were prepared according to a general
2-step synthesis reported previously by Orjales et al. with
only slight modification [22,23]. Commercially available
2-chlorobenzimidazole, in dry DMF was treated with a
slight excess of NaH, (1.1eq). After stirring for 1 hour at
room temperature, one equivalent of the appropriate
alkyl bromide was added slowly and the reaction mixture
heated under reflux for > 5 hours (the reaction was monitored by TLC). Reaction product was partitioned between
water and methylene chloride; organic layer was dried
(Na2SO4) and concentrated in vacuum. The solid residue
was purified by Flash chromatography, which afforded
the corresponding N-substituted 2-Chlorobenzimidazole
intermediates in good yield. The final step involved a nucleophilic substitution of the 2-chloro group by piperazine at high temperatures. The reaction was performed
neat using 4–10 fold excess piperazine and typically heated for a short period only, (30–45 min). Similar work-up
afforded a residue that was purified by either crystallization or chromatography. The yields ranged from 40–95%.
All compounds were characterized by NMR, MS, HRMS,
and /or elemental analysis or were identical to literature
reports.
Materials
D-MEM, Penicillin-Streptomycin, fetal bovine serum, and
Trypsin were obtained from New Life Technologies. 5-HT
and MDL-72222 were obtained from RBI. [3H]-granisetron (84 Ci/mmol) was purchased from New England Nuclear.
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